Esperion Therapeutics Files Q1 2025 10-Q
Ticker: ESPR · Form: 10-Q · Filed: May 8, 2025 · CIK: 1434868
| Field | Detail |
|---|---|
| Company | Esperion Therapeutics, Inc. (ESPR) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Esperion Therapeutics filed its Q1 2025 10-Q, showing current financial status.
AI Summary
Esperion Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 2025. Key financial figures and business segments are presented, reflecting the company's ongoing activities in the pharmaceutical sector.
Why It Matters
This filing provides investors and analysts with the latest financial health and operational performance of Esperion Therapeutics, crucial for understanding its market position and future prospects.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Esperion Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2025-05-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Esperion Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250508 (date) — Filing date
- Ann Arbor, MI (location) — Company headquarters
FAQ
What were Esperion Therapeutics' total revenues for the first quarter of 2025?
The filing indicates revenue data for the period January 1, 2025 to March 31, 2025, but specific total revenue figures are not explicitly stated in the provided text snippet.
What is Esperion Therapeutics' primary business segment?
Esperion Therapeutics operates within the Pharmaceutical Preparations industry, with segments including Product revenue and Collaboration Revenue.
When was Esperion Therapeutics previously known as HDL THERAPEUTICS INC?
The company's name changed from HDL THERAPEUTICS INC on May 13, 2008.
Where is Esperion Therapeutics headquartered?
Esperion Therapeutics is headquartered at 3891 Ranchero Drive, Suite 150, Ann Arbor, MI 48108.
What is the SEC file number for Esperion Therapeutics?
The SEC file number for Esperion Therapeutics is 001-35986.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Esperion Therapeutics, Inc. (ESPR).